Sign in
Stories
Adicet Bio Grants Inducement Stock Options
Share
Adicet Bio Awards Stock Options
Advancements in Gene Editing and Cancer ...
Antibe's Receivership and Delisting
Acquisition Progress Amid Safety Concern
Arcus Biosciences Announces New Employme...
Clarify Pharma Rebrands to File Forge
Overview
API
Adicet Bio granted a non-qualified stock option award to a new hire under Nasdaq Listing Rule 5635(c)(4), offering 7,000 shares with a four-year vesting schedule. This award was issued outside of the stockholder-approved equity incentive plans. Adicet Bio specializes in allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Ask a question
How might the inducement award impact the recruitment strategy and talent retention at Adicet Bio?
In what ways could the focus on gamma delta T cell therapies by Adicet Bio contribute to advancements in treating autoimmune diseases and cancer?
What potential implications could this non-qualified stock option grant have on the company's financial performance and employee motivation?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage